Advance Directives Registry Offers Instant Access

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 9
Volume 5
Issue 9

NEW YORK--Choice In Dying is offering a new service that electronically stores advance directives (living wills and health care proxies). The service provides instant access to these documents with one phone call, thus avoiding the search for documents at a critical time, as, for example, when a patient becomes unconscious or unable to speak for himself.

NEW YORK--Choice In Dying is offering a new service that electronicallystores advance directives (living wills and health care proxies).The service provides instant access to these documents with onephone call, thus avoiding the search for documents at a criticaltime, as, for example, when a patient becomes unconscious or unableto speak for himself.

Choice In Dying is a national, not-for-profit organization dedicatedto fostering communication about complex end-of-life decisionsamong individuals, their loved ones, and health care professionals,and to serving the needs of dying patients and their families.The organization invented the living will in 1967 and has distributedmore than 10 million living wills since that time.

The service, DocuDIAL Advance Directives Registry, provides awallet-sized card containing instructions for family members andhealth care providers on how to retrieve the documents by fax.The service is accessible 24 hours a day, 7 days a week. Peoplecan enroll by calling 1-800-989-WILL (9455). The one-time registrationfee is $55 ($45 for members of Choice In Dying).

Applicants send photocopies of their documents, which are thenreviewed to make sure they meet the applicant's state legal requirementsand have been properly signed and witnessed. The service willnotify registrants of changes in their state laws if these occur.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content